FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...

This article examines viral and non-viral vectors in gene therapy, highlighting their mechanisms, advantages, and limitations ...

Scientists have corrected gene mutations in mice causing an ultra-rare disease by editing DNA directly in the brain with a ...

Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, OCU410ST ...

This article highlights the current state of macromolecular gene delivery systems, their applications, and the ongoing ...

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...

The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...

Gene delivery is a key area in biomedicine, where nucleic acids are delivered into cells to treat diseases by modulating ...

Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

DUBLIN--(BUSINESS WIRE)--The "Gene Delivery Systems - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Gene Delivery Systems was ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Sai Lomte, Tarun. (2024, November 17). Engineered virus-like particles evolve for superior gene ...